The Patent Finder

Mologen AG

Also on record
Records under this name other than the patents Mologen AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.

Back to Mologen AG

PatentTitleStatus Expires Confidence
US 8,017,591Substituted, Non-Coding Nucleic Acid Molecule for Therapeutic and Prophylactic Stimulation of the Immune System in Humans and Higher Animals
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,499,815Multimer for Immunostimulation
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,487,333Combination Comprising Immunostimulatory Oligonucleotides
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,583,581Methods of Treating a Latent HIV-1 Infection Using Non-Coding Deoxyribonucleic Acids
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,006,032Predictive Biomarker for Cancer Therapy
Formerly held
Lapsed on the fee record
Ended Jun 26, 2026 · High confidence
Lapsed on the fee recordEnded Jun 26, 2026High confidence
US 7,635,468Allogeneic Tumor Therapeutic Agent, a Vaccine Using Allogeneic Tumor Cells for the Therapeutic Treatment of Tumor Diseases, and a Method for the Making of Such a Vaccine, and Transfected Human Tumor Cells for Use as a Vaccine
Formerly held
Term ended
Term ended Dec 30, 2024 · High confidence
Term endedTerm ended Dec 30, 2024High confidence
US 9,345,754Allogeneic Tumor Therapeutic Agent, a Vaccine Using Allogeneic Tumor Cells for the Therapeutic Treatment of Tumor Diseases, and a Method for the Making of Such a Vaccine, and Transfected Human Tumor Cells for Use as a Vaccine
Lapsed on the fee record
Ended May 24, 2024 · Medium confidence
Lapsed on the fee recordEnded May 24, 2024Medium confidence
US 9,212,366Immune Modulating Oligonucleotides in Connection with Chemotherapeutic Measures
Formerly held
Lapsed on the fee record
Ended Dec 15, 2023 · High confidence
Lapsed on the fee recordEnded Dec 15, 2023High confidence
US 10,280,424Covalently closed non-coding immunomodulatory DNA construct
Lapsed on the fee record
Ended May 7, 2023 · From the USPTO record
Lapsed on the fee recordEnded May 7, 2023From the USPTO record
US 7,795,406Agent for treating leishmania infections
Lapsed on the fee record
Ended Sep 14, 2022 · From the USPTO record
Lapsed on the fee recordEnded Sep 14, 2022From the USPTO record
10 of 20 patents shown.
Pro members see all 20.
Pro members: see all 20 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited